Skip to content

Alto Neuroscience ANRO Debt-to-equity

Debt-to-equity at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
0.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
0.0×
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
0.0×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
0.0×
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
27.2×+26.1×
LBR
LB Pharmaceuticals Inc Common StockLBRX

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,335%
Enterprise value$630.81M-940%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

Based on the most recent quarter.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's debt-to-equity?
Alto Neuroscience (ANRO) reported debt-to-equity of 0.1× in Q1 2026.
How has Alto Neuroscience's debt-to-equity changed year-over-year?
Alto Neuroscience's debt-to-equity decreased by 52.7% year-over-year, from 0.2× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.